×
About 17,018 results
FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
http://hugin.info/152918/R/2233733/878824.pdf

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP.

Screening for Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults: U...
https://doi.org/10.1001/jama.2018.14741
JAMA , Curry SJ et. al.

Oct 25th, 2018 - Intimate partner violence (IPV) and abuse of older or vulnerable adults are common in the United States but often remain undetected. In addition to the immediate effects of IPV, such as injury and death, there are other health consequences, many with long-term effects, including development of mental health conditions such as depression, posttraumatic stress disorder, anxiety disorders, substan...

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.
https://doi.org/10.1053/j.gastro.2017.12.012
Gastroenterology Hadjiliadis D, Khoruts A et. al.

Dec 31st, 2017 - Improved therapy has substantially increased survival of persons with cystic fibrosis (CF). But the risk of colorectal cancer (CRC) in adults with CF is 5-10 times greater compared to the general population, and 25-30 times greater in CF patients after an organ transplantation. To address this risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommendatio...

Practice Bulletin No. 184: Vaginal Birth After Cesarean Delivery.
https://doi.org/10.1097/AOG.0000000000002398
Obstetrics and Gynecology;

Oct 24th, 2017 - Trial of labor after cesarean delivery (TOLAC) refers to a planned attempt to deliver vaginally by a woman who has had a previous cesarean delivery, regardless of the outcome. This method provides women who desire a vaginal delivery the possibility of achieving that goal-a vaginal birth after cesarean delivery (VBAC). In addition to fulfilling a patient's preference for vaginal delivery, at an ...

Recommendations for Prevention and Control of Influenza in Children, 2017 - 2018.
https://doi.org/10.1542/peds.2017-2550
Pediatrics

Sep 5th, 2017 - This statement updates the recommendations for routine use of the seasonal influenza vaccine and antiviral medications for the prevention and treatment of influenza in children. The American Academy of Pediatrics recommends annual seasonal influenza immunization for everyone 6 months and older, including children and adolescents. Highlights for the upcoming 2017-2018 season include the followin...

Clinical Practice Guideline for Screening and Management of High Blood Pressure in Chil...
https://doi.org/10.1542/peds.2017-1904
Pediatrics Flynn JT, Kaelber DC et. al.

Aug 22nd, 2017 - These pediatric hypertension guidelines are an update to the 2004 "Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents." Significant changes in these guidelines include (1) the replacement of the term "prehypertension" with the term "elevated blood pressure," (2) new normative pediatric blood pressure (BP) tables based on normal-weight ch...

BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1

Aug 20th, 2019 - The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling a...

Unraveling the Safety Profile of Proton-Pump Inhibitors
https://www.jwatch.org/na49660/2019/08/19/unraveling-safety-profile-proton-pump-inhibitors
Journal Watch;

Aug 19th, 2019 - Proton-pump inhibitors (PPIs) provide important clinical benefits for many patients. However, observational studies have suggested an association between PPI use and a variety of adverse events, including dementia, osteoporosis, bone fractures, micronutrient deficiencies, pneumonia, spontaneous bacterial peritonitis, kidney disease, and enteric infections. We have observed that some patients wi...

Maintaining Full Doses of Chemotherapy Can Be Key for Breast Cancer Survival, According to New Research in JNCCN
https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1641

Aug 19th, 2019 - Physicians should attempt to maintain full doses of chemotherapy, especially early in the treatment course, for intermediate or high risk breast cancer patients, according to new research published in the August 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network. The study, which looked at the impact of dose reduction with the adjuvant (post-surgery) chemotherapy combinat...

Insomnia tied to higher risk of heart disease and stroke
https://newsroom.heart.org/news/insomnia-tied-to-higher-risk-of-heart-disease-and-stroke

Aug 18th, 2019 - People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke, according to new research in the American Heart Association’s journal Circulation. Previous observational studies have found an association between insomnia, which affects up to 30% of the general population, and an increased risk of developing heart disease and stroke. These obse...

FDA approves new antibiotic to treat community-acquired bacterial pneumonia
https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia

Aug 18th, 2019 - The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. “This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease,” said Ed Cox, M.D., M.P.H., director of FDA’s Office of Antimicrobial Products. “For managing this serious disease, it is impor...

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.1 “The approval of INREBIC is another important milestone for Celgene and underscores our commitment ...

FDA approves Roche’s Rozlytrek (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
https://www.roche.com/media/releases/med-cor-2019-08-16.htm

Aug 16th, 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has also granted accelerated approval to Rozlytrek for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a...

FDA approves fedratinib for myelofibrosis
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fedratinib-myelofibrosis

Aug 16th, 2019 - On August 16, 2019, the Food and Drug Administration approved fedratinib (INREBIC, Impact Biomedicines, Inc.) for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). Efficacy was investigated in JAKARTA (NCT01437787), a double-blind, randomized, placebo-controlled trial in 289 patients with intermediate-2...

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor F...
https://news.abbvie.com/news/press-releases/abbvie-receives-fda-approval-rinvoq-upadacitinib-an-oral-jak-inhibitor-for-treatment-moderate-to-severe-rheumatoid-arthritis.htm?_ga=2.79140499.665850950.1566223698-1470367535.1566223698

Aug 15th, 2019 - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).1 R...

FDA approves treatment for patients with rare bone marrow disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder

Aug 15th, 2019 - Today, the U.S. Food and Drug Administration approved Inrebic (fedratinib) capsules to treat adult patients with certain types of myelofibrosis. “Prior to today, there was one FDA-approved drug to treat patients with myelofibrosis, a rare bone marrow disorder. Our approval today provides another option for patients,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excelle...

FDA approves first of its kind device to treat pediatric patients with progressive idiopathic scoliosis
https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pediatric-patients-progressive-idiopathic-scoliosis

Aug 15th, 2019 - The U.S. Food and Drug Administration today approved the first spinal tether device intended to be used in children and adolescents to correct the most common form of scoliosis, called idiopathic scoliosis, that has not responded to conservative treatment options, such as external bracing. The device, called The Tether – Vertebral Body Tethering System, is intended to treat growing children and...

Ewing Sarcoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/bone/hp/ewing-treatment-pdq

Aug 15th, 2019 - Ewing sarcoma treatment options include multidrug chemotherapy, surgery, and radiation therapy. Treatment approaches titrate therapeutic aggressiveness to maximizing local control while minimizing morbidity. Get detailed treatment information for Ewing sarcoma in this summary for clinicians.

Childhood Laryngeal Tumors Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/head-and-neck/hp/child/laryngeal-treatment-pdq?cid=eb_govdel

Aug 15th, 2019 - Treatment for children with laryngeal tumors depends upon the type; most are rhabdomyosarcoma and treated with chemotherapy and radiation therapy. Squamous cell carcinoma is managed with surgery and radiation therapy. Get detailed treatment information in this summary for clinicians.

Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-soft-tissue-treatment-pdq?cid=eb_govdel

Aug 15th, 2019 - Treatment options for children with soft tissue sarcoma include surgery, radiation therapy, chemotherapy, and targeted therapy. Get detailed information about the treatment of newly diagnosed, metastatic, and recurrent soft tissue sarcoma in this summary for clinicians.